Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab

Georgina Long, BSc, PhD, MBBS, FRACP, FAHMS, The University of Sydney, Sydney, Australia, comments on data from the Phase II LEAP-004 study (NCT03776136), which assessed lenvatinib and pembrolizumab in patients with melanoma who progressed on PD-1/L1 inhibitors such as ipilimumab, unlike in the NeoPeLe trial (NCT04207086), which only recruited patients with resectable melanoma. Lenvatinib and pembrolizumab represent a promising therapy for these patients of high unmet need, where a durable response was recorded in patients receiving the investigational treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.